70261-82-4

Usage

Uses

Used in Pharmaceutical Industry:
4-[(4-Methylpiperazin-1-yl)methyl]aniline is used as an intermediate in the synthesis of aminopyridopyrimidinones, which are known as tyrosine kinase inhibitors. These inhibitors play a significant role in the development of anticancer agents, as they can help regulate the activity of enzymes involved in cell growth and division, thereby preventing the uncontrolled proliferation of cancer cells.
Additionally, 4-[(4-Methylpiperazin-1-yl)methyl]aniline is utilized in the synthesis of piperazinyltrifluoromethylphenylquinolinylbenzonaphthyridinone derivatives. These compounds exhibit anticancer activities and are being investigated for their potential use in the treatment of various types of cancer. The incorporation of the methylpiperazine group in these derivatives may enhance their pharmacological properties, such as solubility, stability, and bioavailability, making them more effective in combating cancer cells.

InChI:InChI=1/C12H19N3/c1-14-6-8-15(9-7-14)10-11-2-4-12(13)5-3-11/h2-5H,6-10,13H2,1H3/p+2

Upstream product

• 100-14-1 4-nitrobenzyl chloride 
• 109-01-3 1-methyl-piperazine 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 99-99-0 1-methyl-4-nitrobenzene 
• 555-16-8 4-nitrobenzaldehdye 
• 70261-81-3 4-(4-nitrobenzyl)-1-methylpiperazine 
• 150-13-0 4-amino-benzoic acid 
• 55121-99-8 (4-aminophenyl)(4-methylpiperazin-1-yl)methanone 

Downstream Products

• 80166-00-3 4-[(4-methylpiperazin-1-yl)methyl]phenol 
• 258876-65-2 [1-Biphenyl-4-yl-meth-(E)-ylidene]-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine 
• 70261-74-4 4-[[4-[[4-(methyl)-1-piperazinyl]methyl]phenyl]amino]-7-(trifluoromethyl)quinoline 
• 1207601-60-2 2,4-dihydroxy-5-isopropyl-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzothioamide 
• 1170679-07-8 3-(2-Ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-ylmethyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile 
• 1313481-16-1 6-chloro-2-methoxy-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)acridin-9-amine 
• 1350443-64-9 4-(1H-imidazol-1-yl)-N-[4-(4-methylpiperazin-1-ylmethyl)phenyl]benzamide 
• 1350443-65-0 N-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-4-[(quinolin-5-yl)amino]benzamide 

Relevant academic research and scientific papers

(4 - Fused heterocycle-substituted amino)-3 - 1H-pyrazolecarboxamide compound and application thereof

The invention relates to the field of pharmaceutical chemistry and in particular relates to 4-(fused-heterocycle substituted amino)-1H-pyrazol-3-formamide compounds and application thereof, preparation methods of the compounds, pharmaceutical compositions

4-(saturated aliphatic ring-pyrimidine/pyridine substituted)amino-1H-3-pyrazol carboxamide FMS-like tyrosine kinase 3 (FLT3) inhibitor and application thereof

The invention relates to 4-(saturated aliphatic ring-pyrimidine/pyridine substituted)amino-1H-3-pyrazol carboxamide FMS-like tyrosine kinase 3 (FLT3) inhibitor, an application thereof, or pharmaceutically acceptable salt, solvate, isomer, ester, acid, met

Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia

A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.

BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

Discovery of the selective and efficacious inhibitors of FLT3 mutations

Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy. Starting from the lead compound LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivatives were synthesized to improve the FLT3 inhibitory potency and selectivity. Among them, compound 50 was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib. Compound 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants. Inversely, compound 50 displayed no cytotoxicity to FLT3-independent cells, and the biochemical analyses showed that its effects were related to the inhibition of FLT3 signal pathways. Additionally, compound 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry. Moreover, compound 50 showed enhanced metabolic stability. Altogether, it was concluded that compound 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.

Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance

Simutaneous targeting all Raf isoforms offers the prospect of enhanced efficacy as well as reduced potential for resistance. Described herein is the discovery and characterization of a series of pyrimidine scaffold with DFG-out conformation as potent Pan-Raf inhibitors. Among them, I-41 with excellent Pan-Raf potency demonstrates inhibitory activity against BRafWTphenotypic melanoma and BRafV600Ephenotypic colon cells. The western blot results for the Erk inhibition in human melanoma SK-Mel-2?cell lines showed I-41 inhibited the proliferation of SK-Mel-2?cell lines without paradoxical activation of Erk, which supported I-41 may become a good candidate compound to overcome the resistance of melanoma against the current BRafV600Einhibitor therapy. I-41 also have a favorable pharmacokinetic profile in rat. Synthesis, SAR, lead selection, and evaluation of the key compounds studies are described.

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT

In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in

Beta-carboline derivative targeted to CDK and DNA and preparation method and medical application thereof

The invention discloses a beta-carboline derivative targeted to CDK and DNA and a preparation method and medical application thereof. The beta-carboline derivative has a structure shown in the general formula I in the description. The compound can be applied in combination with other antitumor drugs and can also be applied in combination with radiotherapy. The antitumor drugs or radiotherapy and the compound can be applied at the same time or at different times. The combined therapy can perform a synergistic effect, and thus the therapeutic effect can be easily improved.

4-(aromatic heterocyclic substituted)amino-1H-3-pyrazolecarboxamide FLT3 (Fms-like tyrosine kinase) inhibitor and application thereof

The invention relates to a novel 4-(aromatic heterocyclic substituted)amino-1H-3-pyrazolecarboxamide compound or pharmaceutically acceptable salts, solvates, isomers, esters, acids, metabolites or pro-drugs thereof and a preparation method thereof. The in

2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application

The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.